SCHEDULE: Vanguard Reports 0% Veracyte Stake Post-Internal Realignment

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Veracyte Inc. due to an internal organizational realignment.

Summary

• The Vanguard Group filed an Amendment No. 6 to its Schedule 13G for Veracyte Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares of Veracyte Inc., representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, effective January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The underlying investment strategies pursued by these subsidiaries and/or business divisions remain the same as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Veracyte Inc. as the change in beneficial ownership reporting by Vanguard is due to an internal realignment and not a strategic divestment, thus not reflecting a change in investment sentiment towards Veracyte.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Veracyte Inc.'s future performance or The Vanguard Group's investment intentions beyond the reporting change.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how a major institutional investor, The Vanguard Group, reports its holdings, rather than a strategic divestment from Veracyte Inc. This type of internal realignment for reporting purposes is not uncommon among large asset managers and does not necessarily indicate a change in investment thesis for the underlying company.

Stakeholder Impact

• Shareholders of Veracyte Inc. may initially perceive a major institutional investor's reported ownership dropping to 0% as negative, but the accompanying explanation clarifies it as a procedural reporting change rather than a true divestment, mitigating potential negative sentiment.

Key Dates

Recommendation

The filing primarily details a procedural change in how The Vanguard Group reports its beneficial ownership due to an internal realignment, rather than a change in its investment strategy or a divestment from Veracyte Inc. As such, it does not provide new fundamental information about Veracyte Inc. that would warrant a change in investment recommendation. Investors should hold their position and monitor future company-specific news.

Keywords

Vanguard Group, Veracyte Inc, Schedule 13G, Beneficial Ownership, Internal Realignment, SEC Filing, Common Stock, Institutional Investor